Oncology

Novartis ventures itself into developing new editing technology Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&D work in the arena of cell and gene therapy. The deal involves Novartis using the gene editing technology of Homology for developing new treatments related to ophthalmic and hemoglobinopathy diseases. The financial details of the deal has not been revealed but there is an update that Homology will receive an upfront payment as well as an equity investment from Novartis. This has been done to advance the program and explore opportunities for this technology platf...